{"id":477679,"date":"2020-04-03T12:10:01","date_gmt":"2020-04-03T12:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477679"},"modified":"2020-04-03T12:10:01","modified_gmt":"2020-04-03T12:10:01","slug":"focal-segmental-glomerulosclerosis-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-pipeline-insight-2020_477679.html","title":{"rendered":"Focal Segmental Glomerulosclerosis Pipeline Insight, 2020"},"content":{"rendered":"
\"Focal<\/a><\/div>\n

 <\/p>\n

DelveInsight has launched a new report on Focal Segmental Glomerulosclerosis Pipeline Insight, 2020<\/strong><\/p>\n

“Focal Segmental Glomerulosclerosis (FSGS) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis (FSGS) market. A detailed picture of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape is provided, which includes the disease overview and Focal Segmental Glomerulosclerosis (FSGS) treatment guidelines. The assessment part of the report embraces in-depth Focal Segmental Glomerulosclerosis (FSGS) commercial assessment and clinical assessment of the Focal Segmental Glomerulosclerosis (FSGS) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Focal Segmental Glomerulosclerosis (FSGS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed.FSGS may be found either as primary or secondary forms. Primary FSGS sometimes has no identifiable cause or known etiology and linked to genetic mutations in podocyte-specific proteins, while secondary FSGS might include familial\/genetic forms, virus-associated forms, drug-induced forms, and forms mediated by adaptive structural-functional response.<\/div>\n
 <\/div>\n
The clinical features of FSGS include peripheral edema, marked proteinuria, hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. The pathogenesis of FSGS is very complex, mostly podocyte injury and parietal epithelial cells lining Bowman’s capsule play a central role in the disease progression. FSGS is classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion (Columbia Classification).<\/div>\n
 <\/div>\n
\"\"<\/div>\n
 <\/div>\n
Request for :- <\/strong><\/em>FSGS pipeline free sample page<\/a><\/div>\n
 <\/div>\n
Pipeline Development Activities<\/strong><\/em><\/div>\n
\n

The report provides insights into: <\/p>\n